Summary
Definition
History and exam
Key diagnostic factors
- presença de fatores de risco
- claudicação dos membros superiores ou inferiores
- ausência de pulso(s)
- pressões arteriais desiguais
- sopros vasculares
- febre baixa
Other diagnostic factors
- ataque isquêmico transitório (AIT)
- mialgia
- artralgia
- perda de peso
- fadiga
- tontura no esforço físico dos membros superiores
- hipertensão
- acidente vascular cerebral (AVC)
- dor torácica
- dor abdominal
- diarreia
- dispneia
- hemoptise
- sudorese noturna
- vertigem
- síncope
- cefaleia
- sopro cardíaco
- sintomas visuais
- eritema nodoso
- pioderma gangrenoso
Risk factors
- predisposição genética
- sexo feminino
- idade <40 anos
- etnicidade asiática
Diagnostic tests
1st tests to order
- velocidade de hemossedimentação (VHS)
- proteína C-reativa
- angiotomografia (ATG)
- angiografia por ressonância magnética (ARM)
Tests to consider
- ultrassonografia com Doppler
- tomografia por emissão de pósitrons com fluordesoxiglucose radiomarcada (PET-FDG)
Treatment algorithm
todos os pacientes
Contributors
Authors
Kenneth J. Warrington, MD
Professor of Medicine
Mayo Clinic College of Medicine
Rochester
MN
Disclosures
KJW declares that he has received clinical trial support from Eli Lilly, BMS, and Kiniksa. He has received consulting fees and honoraria from Amgen and Sanofi. KJW is an author of a number of references cited in this topic.
Acknowledgements
Dr Kenneth J. Warrington would like to gratefully acknowledge Dr Steven R. Ytterberg and Dr Eric L. Matteson, previous contributors to this topic.
Disclosures
SRY declares that he was a sub-awardee of a grant from the US Food and Drug Administration for a pilot study of abatacept, a treatment for Takayasu's arteritis. SRY is also a member of the steering committee at the Vasculitis Clinical Research Committee. ELM declares that he has no competing interests.
Peer reviewers
Loic P. Guillevin, MD
Internal Medicine
Hopital Cochin-Paris University
St-Jacques
Paris
France
Disclosures
LPG declares that he has no competing interests.
Gene G. Hunder, MD
Department of Medicine
Division of Rheumatology
Mayo Clinic
Rochester
MN
Disclosures
GGH is an author of a reference cited in this topic. GGH declares that he has no other competing interests.
References
Key articles
Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003 Jul 10;349(2):160-9. Abstract
Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am. 1995 Nov;21(4):1041-58. Abstract
Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65.Full text Abstract
Pugh D, Karabayas M, Basu N, et al. Large-vessel vasculitis. Nat Rev Dis Primers. 2022 Jan 6;7(1):93.Full text Abstract
Isselbacher EM, Preventza O, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 Dec 13;80(24):e223-393. Abstract
Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022 Dec;81(12):1654-60.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Arterite de células gigantes
- Hipertensão essencial
- Sífilis
More DifferentialsGuidelines
- 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis
- 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer